[Clinical and biological efficacy of tocilizumab in giant cell arteritis: report of three patients and literature review].
Treatment of giant cell arteritis is based on prolonged corticosteroid therapy but adverse side effects are common especially in the elderly. We report three patients with giant cell vasculitis treated by tocilizumab, an interleukin-6 receptor antibody, owing to resistance or intolerance to corticosteroid therapy. A favorable outcome was rapidly observed both on clinical and biological data allowing a corticoid therapy sparing. Tocilizumab is a promising treatment of giant cell arteritis but controlled trials are needed to confirm its efficacy.